ArticleBioconjugate chemistry2011
Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers.
Article in Bioconjugate chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.Nature communications · 2023Article
- Cell Uptake of Steroid-BODIPY Conjugates and Their Internalization Mechanisms: Cancer Theranostic Dyes.International journal of molecular sciences · 2023Article
- Water-Soluble Nanoconjugate for Enhanced Cellular Delivery of Receptor-Targeted Magnetic Resonance Contrast Agents.Bioconjugate chemistry · 2019Article
- Article
- PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.Oncogene · 2017Article
- Detection of Ciprofloxacin in Urine through Sensitized Lanthanide Luminescence.Sensors (Basel, Switzerland) · 2016Article
- Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.Frontiers in oncology · 2016Article
- Multimeric Near IR-MR Contrast Agent for Multimodal In Vivo Imaging.Journal of the American Chemical Society · 2015Article
- Easy access to heterobimetallic complexes for medical imaging applications via microwave-enhanced cycloaddition.Beilstein journal of organic chemistry · 2015Article
- Progesterone-targeted magnetic resonance imaging probes.Bioconjugate chemistry · 2014Article
- Lanthanide probes for bioresponsive imaging.Chemical reviews · 2014Review
- Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.Magnetic resonance in medicine · 2013Article
- Analytical methods for characterizing magnetic resonance probes.Analytical chemistry · 2012Article
- Biological characterization of non-steroidal progestins from botanicals used for women's health.Steroids · 2012Article
- Synthesis, Characterization, and in vitro Testing of a Bacteria-Targeted MR Contrast Agent.European journal of inorganic chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Progesterone receptor (PR) is strongly associated with disease prognosis and therapeutic efficacy in hormone-related diseases such as endometriosis and breast, ovarian, and uterine cancers. Receptor status is currently determined by immunohistochemistry assays. However, noninvasive PR imaging agents could improve disease detection and help elucidate pathological molecular pathways, leading to new therapies and animal disease models. A series of water-soluble PR-targeted magnetic resonance imaging (MRI) probes were synthesized using Cu(I)-catalyzed click chemistry and evaluated in vitro and in vivo. These agents demonstrated activation of PR in vitro and preferential accumulation in PR(+) compared to PR(-) human breast cancer cells with low toxicity. In xenograft tumor models, the agents demonstrated enhanced signal intensity in PR(+) tumors compared to PR(-) tumors. The results suggest that these agents may be promising MRI probes for PR(+) diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.